Two Molecules, Side by Side

The short version

This page lines up NAD+ and MOTS-c on the dimensions that matter most: molecular class, where each has been most studied, how strong that evidence is, how each was administered in studies, its regulatory standing, and its single most important caution. The headline: both touch the cellular machinery of aging, but from genuinely different directions and at different stages of human evidence. NAD+ has multiple randomized human trials — consistently raising blood NAD+ with some functional improvements — while MOTS-c has impressive animal-model data and one human biomarker-association study. Neither is an approved medicine, and this desk presents no human dose for either.

The comparison matrix

Molecular class

The two are fundamentally different in kind. NAD+ is a dinucleotide — two nucleotide units joined by phosphate groups — that the body has been making and cycling since the earliest stages of cellular evolution. It is so central to metabolism that virtually every cell in every living organism carries it. MOTS-c, by contrast, is a peptide: sixteen amino acids, encoded within the mitochondrial genome in a region that was long thought to produce only structural RNA, not protein. Studying MOTS-c means studying a molecular signal the mitochondria generate themselves — something closer to a metabolic hormone than a coenzyme ^[11].

Most-studied in

Each molecule has a home territory that reflects its mechanism. NAD+ research spans metabolic aging broadly: energy metabolism, sirtuin-mediated gene regulation, PARP-dependent DNA repair, and the CD38-driven NAD+ consumption that rises with aging and inflammation ^[4]. In humans the sharpest specific finding is improved muscle insulin sensitivity in prediabetic women ^[3]. MOTS-c research centers on skeletal muscle glucose handling and physical performance — consistent with its AMPK-activating, insulin-sensitizing mechanism — and extends into cardiac metabolism and the mitochondria-to-nucleus signaling story ^[6][9][11].

Evidence base (model)

This is where the two genuinely separate, though perhaps not in the direction one might expect. NAD+ — despite being older science — has more human clinical trial data: multiple randomized controlled trials consistently demonstrating blood NAD+ elevation, with one trial showing improved walking distance ^[2] and another muscle insulin sensitivity ^[3]. What it lacks is hard long-term human outcome data on aging or disease. MOTS-c has a richer and more mechanistically sophisticated animal record — prevention of obesity and insulin resistance ^[11], extension of physical performance across age groups ^[9], cardiac protection in a diabetic rat model ^[12], a direct molecular target identified ^[6] — plus a prospective human cohort association study ^[7]. What it lacks is any human interventional trial at all.

Administration studied

Routes track the type of molecule and the research question. NAD+ precursors (NMN, NR) are studied as oral supplements, which is how they are commercially available; the human trials used oral administration ^[2][3][5]. IV NAD+ exists in the wellness clinic setting as a compounded infusion, but this route is associated with discomfort if infused too quickly and has been subject to a compounding-quality recall ^[4]. MOTS-c in animal studies has been given subcutaneously or intraperitoneally; no validated human route, dose, or pharmacokinetic profile exists ^[8]. This is the clearest practical difference between the two from a research-readiness standpoint.

Regulatory and anti-doping status

NAD+ and its precursors occupy a nuanced regulatory position: sold as dietary supplements, not approved drugs, with the FDA's contested position on NMN creating marketplace uncertainty ^[4]. IV/injectable NAD+ is compounded, not FDA-approved, and a Class I recall has been issued for endotoxin contamination in at least one compounded product ^[4]. WADA does not list NAD+ precursors as prohibited.

MOTS-c sits in a different category entirely: a research chemical with no approved indication, not a supplement, and explicitly treated as prohibited under anti-doping frameworks that cover peptide and metabolic-modulator agents ^[8]. Any competitive athlete should treat it as prohibited at all times.

Key caution

For NAD+, the defining caution is that the most consistently demonstrated effect — raising blood NAD+ — has not yet been linked to hard clinical outcomes in humans. A 2025 Nature Metabolism review, which represents the most current authoritative synthesis of the human trial evidence, concluded human efficacy data are still limited and tissue-specific NAD+ dynamics sparse ^[1]. For MOTS-c the caution is more fundamental: there are no human interventional trials, no validated human pharmacokinetics, and the full picture of human safety is unknown ^[8]. Together they illustrate a recurring theme in longevity research: compelling mechanisms, sophisticated preclinical evidence, and human outcome data that are still catching up.